Genetics of the Combined Pulmonary Fibrosis and Emphysema Syndrome

NCT ID: NCT02439528

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-25

Study Completion Date

2018-12-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The combined pulmonary fibrosis and emphysema syndrome (CPFE) individualized by our group in 2005 is characterized by an often severe dyspnea, almost exclusive male predominance, and often major, profound impairment of gas exchange contrasting with preserved lung volumes and absence of airflow obstruction, and a high risk of pre-capillary pulmonary hypertension responsible for increased mortality. Almost all patients are smokers or ex-smokers. There are some arguments in favor of genetic abnormalities in this syndrome of unknown etiology (other than smoking) including short telomeres and mutations in the telomerase complex genes. There are also emphysematous lesions, in patients with familial pulmonary fibrosis, with mutations in the SFTPC gene (surfactant protein C), and reported cases of CPFE syndrome with SFTPC mutation. No large genetic studies have been conducted to date in the CPFE syndrome. Our main hypothesis is that the proportion of subjects with short telomeres is higher among patients with CPFE syndrome than in subjects of similar age with idiopathic pulmonary fibrosis but without emphysema. It has previously been shown that mutations in the telomerase TERT or TERC genes are mostly found in people whose telomeres are abnormally short. The investigators propose to use that test to identify patients most likely carrying a mutation, and to seek, among them, the mutations in the TERT or TERC telomerase genes. The objective of the study is to compare the proportion of patients with short telomeres in the group of patients with CPFE syndrome to that of other patients (with idiopathic pulmonary fibrosis without emphysema, or with emphysema without fibrosis).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Combined Pulmonary Fibrosis and Emphysema Syndrome Pulmonary Fibrosis Emphysema Healthy Subjects

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

pulmonary fibrosis syndrome genetic emphysema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Combined pulmonary fibrosis and emphysema syndrome

Genetic analysis on patients with combined pulmonary fibrosis and emphysema syndrome.

Group Type OTHER

Genetic analysis

Intervention Type GENETIC

One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.

The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis.

Pulmonary fibrosis

Genetic analysis on patients with pulmonary fibrosis.

Group Type OTHER

Genetic analysis

Intervention Type GENETIC

One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.

The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis.

Emphysema

Genetic analysis on patients with emphysema.

Group Type OTHER

Genetic analysis

Intervention Type GENETIC

One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.

The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis.

Healthy subject

Genetic analysis on healthy subject.

Group Type OTHER

Genetic analysis

Intervention Type GENETIC

One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.

The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genetic analysis

One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.

The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 and 80 years old.
* Patient with Idiopathic Pulmonary Fibrosis Or
* Patient with emphysema Or
* Patient with combined pulmonary fibrosis and emphysema syndrome Or
* Patient reporting no chronic lung disease

Exclusion Criteria

* Other causes of interstitial lung disease or context:

* Connective
* Pneumonia drug
* Pneumoconiosis
* Sarcoidosis
* histiocytosis, lymphangioleiomyomatosis, etc.
* Refusal to participate in the study or to sign the consent
* Inability to give informed about the information
* Woman breastfeeding or pregnant
* No coverage for Social Security
* Deprivation of Civil Rights
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vincent COTTIN, MD

Role: PRINCIPAL_INVESTIGATOR

Hospices Civils de Lyon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital pneumologique et cardiovasculaire Louis Pradel, HCL

Bron, , France

Site Status

Hôpital Albert Michallon, CHU de Grenoble

Grenoble, , France

Site Status

Hôpital Nord, CHU de Saint-Etienne

Saint-Etienne, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013.819

Identifier Type: -

Identifier Source: org_study_id